Now showing items 1-10 of 10

    • AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer. 

      Kubli, SP; Bassi, C; Roux, C; Wakeham, A; Göbl, C; Zhou, W; Jafari, SM; Snow, B; Jones, L; Palomero, L; Thu, KL; Cassetta, L; Soong, D; Berger, T; Ramachandran, P; Baniasadi, SP; Duncan, G; Lindzen, M; Yarden, Y; Herranz, C; Lazaro, C; Chu, MF; Haight, J; Tinto, P; Silvester, J; Cescon, DW; Petit, A; Pettersson, S; Pollard, JW; Mak, TW; Pujana, MA; Cappello, P; Gorrini, C (2019-02-07)
      Cancer cells have higher reactive oxygen species (ROS) than normal cells, due to genetic and metabolic alterations. An emerging scenario is that cancer cells increase ROS to activate protumorigenic signaling while activating ...
    • Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead. 

      Shrestha, S; Morcavallo, A; Gorrini, C; Chesler, L
      The constitutive and dysregulated expression of the transcription factor MYCN has a central role in the pathogenesis of the paediatric brain tumour medulloblastoma, with an increased expression of this oncogene correlating ...
    • Glutathione Metabolism: An Achilles' Heel of ARID1A-Deficient Tumors. 

      Gorrini, C; Mak, TW (2019-02)
      In this issue of Cancer Cell, Ogiwara et al. describe a novel link between the epigenetic regulator ARID1A and glutathione metabolism in cancer that is mediated by regulation of the cystine/glutamate transporter XCT. This ...
    • Glutathione Primes T Cell Metabolism for Inflammation. 

      Mak, TW; Grusdat, M; Duncan, GS; Dostert, C; Nonnenmacher, Y; Cox, M; Binsfeld, C; Hao, Z; Brüstle, A; Itsumi, M; Jäger, C; Chen, Y; Pinkenburg, O; Camara, B; Ollert, M; Bindslev-Jensen, C; Vasiliou, V; Gorrini, C; Lang, PA; Lohoff, M; Harris, IS; Hiller, K; Brenner, D (2017-04)
      Activated T cells produce reactive oxygen species (ROS), which trigger the antioxidative glutathione (GSH) response necessary to buffer rising ROS and prevent cellular damage. We report that GSH is essential for T cell ...
    • Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis. 

      Herranz, C; Mateo, F; Baiges, A; Ruiz de Garibay, G; Junza, A; Johnson, SR; Miller, S; García, N; Capellades, J; Gómez, A; Vidal, A; Palomero, L; Espín, R; Extremera, AI; Blommaert, E; Revilla-López, E; Saez, B; Gómez-Ollés, S; Ancochea, J; Valenzuela, C; Alonso, T; Ussetti, P; Laporta, R; Xaubet, A; Rodríguez-Portal, JA; Montes-Worboys, A; Machahua, C; Bordas, J; Menendez, JA; Cruzado, JM; Guiteras, R; Bontoux, C; La Motta, C; Noguera-Castells, A; Mancino, M; Lastra, E; Rigo-Bonnin, R; Perales, JC; Viñals, F; Lahiguera, A; Zhang, X; Cuadras, D; van Moorsel, CHM; van der Vis, JJ; Quanjel, MJR; Filippakis, H; Hakem, R; Gorrini, C; Ferrer, M; Ugun-Klusek, A; Billett, E; Radzikowska, E; Casanova, Á; Molina-Molina, M; Roman, A; Yanes, O; Pujana, MA (2021-08-11)
      Inhibition of mTOR is the standard of care for lymphangioleiomyomatosis (LAM). However, this therapy has variable tolerability and some patients show progressive decline of lung function despite treatment. LAM diagnosis ...
    • Immune Cell Associations with Cancer Risk. 

      Palomero, L; Galván-Femenía, I; de Cid, R; Espín, R; Barnes, DR; Cimba; Blommaert, E; Gil-Gil, M; Falo, C; Stradella, A; Ouchi, D; Roso-Llorach, A; Violan, C; Peña-Chilet, M; Dopazo, J; Extremera, AI; García-Valero, M; Herranz, C; Mateo, F; Mereu, E; Beesley, J; Chenevix-Trench, G; Roux, C; Mak, T; Brunet, J; Hakem, R; Gorrini, C; Antoniou, AC; Lázaro, C; Pujana, MA (2020-07)
      Proper immune system function hinders cancer development, but little is known about whether genetic variants linked to cancer risk alter immune cells. Here, we report 57 cancer risk loci associated with differences in ...
    • Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2. 

      Inoue, S; Li, WY; Tseng, A; Beerman, I; Elia, AJ; Bendall, SC; Lemonnier, F; Kron, KJ; Cescon, DW; Hao, Z; Lind, EF; Takayama, N; Planello, AC; Shen, SY; Shih, AH; Larsen, DM; Li, Q; Snow, BE; Wakeham, A; Haight, J; Gorrini, C; Bassi, C; Thu, KL; Murakami, K; Elford, AR; Ueda, T; Straley, K; Yen, KE; Melino, G; Cimmino, L; Aifantis, I; Levine, RL; De Carvalho, DD; Lupien, M; Rossi, DJ; Nolan, GP; Cairns, RA; Mak, TW (2016-08)
      Mutations in the isocitrate dehydrogenase-1 gene (IDH1) are common drivers of acute myeloid leukemia (AML) but their mechanism is not fully understood. It is thought that IDH1 mutants act by inhibiting TET2 to alter DNA ...
    • Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. 

      Roux, C; Jafari, SM; Shinde, R; Duncan, G; Cescon, DW; Silvester, J; Chu, MF; Hodgson, K; Berger, T; Wakeham, A; Palomero, L; Garcia-Valero, M; Pujana, MA; Mak, TW; McGaha, TL; Cappello, P; Gorrini, C (2019-03)
      The combination of immune checkpoint blockade with chemotherapy is currently under investigation as a promising strategy for the treatment of triple negative breast cancer (TNBC). Tumor-associated macrophages (TAMs) are ...
    • SBDS-Deficient Cells Have an Altered Homeostatic Equilibrium due to Translational Inefficiency Which Explains their Reduced Fitness and Provides a Logical Framework for Intervention. 

      Calamita, P; Miluzio, A; Russo, A; Pesce, E; Ricciardi, S; Khanim, F; Cheroni, C; Alfieri, R; Mancino, M; Gorrini, C; Rossetti, G; Peluso, I; Pagani, M; Medina, DL; Rommens, J; Biffo, S (2017-01-05)
      Ribosomopathies are a family of inherited disorders caused by mutations in genes necessary for ribosomal function. Shwachman-Diamond Bodian Syndrome (SDS) is an autosomal recessive disease caused, in most patients, by ...
    • The PTEN and ATM axis controls the G1/S cell cycle checkpoint and tumorigenesis in HER2-positive breast cancer. 

      Bassi, C; Fortin, J; Snow, BE; Wakeham, A; Ho, J; Haight, J; You-Ten, A; Cianci, E; Buckler, L; Gorrini, C; Stambolic, V; Mak, TW (2021-05-31)
      The tumor suppressor PTEN is disrupted in a large proportion of cancers, including in HER2-positive breast cancer, where its loss is associated with resistance to therapy. Upon genotoxic stress, ataxia telangiectasia mutated ...